In glioblastoma, breast, and colorectal tumors, there was also an enrichment of alternative angiogenic factors, including biglycan, ANGPT2, HPSG2, KDR, COL4A1, COL4A2, VWA1, and TIMP1, which may likely compensate for VEGF blockade [23,24,25]. This evidence concerns the gene ANGPT2 and glioblastoma.